Lisata Therapeutics, Inc. (LSTA) company profile

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing treatments for solid tumors and other serious conditions. The company's lead investigational drug candidate is certepetide, which operates via the C-end rule active transport pathway to facilitate deeper penetration of anti-cancer therapies into tumors while altering the tumor microenvironment. Lisata collaborates with biopharmaceutical partners and researchers to evaluate the drug alongside chemotherapy, immunotherapy, and RNA-based treatments for cancer patients.

The business operates as a Delaware corporation with its principal executive offices situated in Basking Ridge, New Jersey. In addition to domestic activities, Lisata conducts research collaborations, patent prosecutions, and clinical studies across multiple countries, including completed and ongoing trials in the United States, China, Australia, and New Zealand.

Summary of the business section of Lisata Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“As of December 31, 2025, we had 21 full-time employees.”